Principles of antipsychotic prescribing for policy makers, circa 2008. Translating knowledge to promote individualized treatment.
about
Evaluation of the clinical efficacy of asenapine in schizophreniaCan authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications.Tying comparative effectiveness information to decision-making and the future of comparative effectiveness research designs: the case for antipsychotic drugs.Characteristics of bipolar disorder patients treated with immediate- and extended-release quetiapine in a real clinical setting: a longitudinal, cohort study of 1761 patients.Differential use of extended and immediate release quetiapine: a retrospective registry study of Finnish inpatients with schizophrenia spectrum and bipolar disorders.Use of quetiapine XR and quetiapine IR in clinical practice for hospitalized patients with schizophrenia: a retrospective study.Are we using excessive neuroleptics? An argument for systematic neuroleptic dose reduction in stable patients with schizophrenia with specific reference to clozapine.Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries.A systematic and critical review of model-based economic evaluations of pharmacotherapeutics in patients with bipolar disorder.Generic atypical antipsychotic drugs in Belgium: their influence and implications.Population study of disease burden, management, and treatment of bipolar disorder in Sweden: a retrospective observational registry study.A Review of Clinical and Economic Evaluations Applied to Psychotropic Therapies Used in the Treatment of Schizophrenia in Argentina.Costs in the Treatment of Schizophrenia in Adults Receiving Atypical Antipsychotics: An 11-Year Cohort in Brazil
P2860
Q24630385-7BFC2E46-80EF-487B-A43B-E676D4084D7BQ33816182-979D6367-EC57-44FC-90F6-54C471161213Q34541147-1CBA490A-A0B5-46AA-9741-4AC72B7B2983Q35044192-C047A10A-F007-49C8-9A4E-5006FAA72ECFQ36081021-A7AC489A-DF59-4AD1-A007-FC7EC8DC7A7EQ37079066-E7A35E56-9FDA-4365-B5B4-1874EE7171D4Q37760926-26FFA995-88CF-4E62-95A9-052B4F546059Q38131544-34BBD435-82D8-416F-9826-8B08731854E0Q38212591-F9E619A6-4156-416D-B5B6-2901ADA5CEFBQ45809881-87FEB021-11BA-4B41-A414-45A8A504523AQ48248419-7BA4FFC9-BFBB-4DEE-B3FD-391819296AB9Q52603247-FF2CCF81-B653-4C21-A935-6E218AE7EA89Q58817750-0EA14453-BF60-42E8-A76F-20EC5E99ADD4
P2860
Principles of antipsychotic prescribing for policy makers, circa 2008. Translating knowledge to promote individualized treatment.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 02 April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Principles of antipsychotic pr ...... mote individualized treatment.
@en
Principles of antipsychotic pr ...... mote individualized treatment.
@nl
type
label
Principles of antipsychotic pr ...... mote individualized treatment.
@en
Principles of antipsychotic pr ...... mote individualized treatment.
@nl
prefLabel
Principles of antipsychotic pr ...... mote individualized treatment.
@en
Principles of antipsychotic pr ...... mote individualized treatment.
@nl
P2093
P2860
P356
P1476
Principles of antipsychotic pr ...... mote individualized treatment.
@en
P2093
Alan Radke
Dale Svendsen
George Parker
Joseph Parks
Mary Diamond
May-Ellen Foti
Rajiv Tandon
Robert Eilers
P2860
P304
P356
10.1093/SCHBUL/SBN019
P407
P577
2008-04-02T00:00:00Z